{"id":"erythropoietin-alpha","safety":{"commonSideEffects":[{"rate":"2-5%","effect":"Thromboembolism"},{"rate":"10-20%","effect":"Hypertension"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This binding activates the JAK2/STAT5 signaling pathway, leading to increased production of red blood cells. Erythropoietin alpha is a recombinant form of the naturally occurring hormone erythropoietin, which is produced by the kidneys in response to hypoxia.","oneSentence":"Erythropoietin alpha stimulates erythropoiesis by binding to the erythropoietin receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:59:44.756Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease"},{"name":"Anemia associated with chemotherapy"}]},"trialDetails":[{"nctId":"NCT00999583","phase":"PHASE3","title":"High Dose of Erythropoietin Analogue After Cardiac Arrest","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2009-10","conditions":"Comatose Survivors of Cardiac Arrest","enrollment":500},{"nctId":"NCT06490601","phase":"PHASE2","title":"Long Term Beta Thalassemia Treatment: Findings From The Extension Period","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan","startDate":"2022-04-01","conditions":"Fetal Hemoglobin, Beta-Thalassemia, Hemoglobinopathies","enrollment":30},{"nctId":"NCT01196715","phase":"PHASE3","title":"Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Barts & The London NHS Trust","startDate":"2010-11-01","conditions":"Myelodysplastic Syndrome","enrollment":360},{"nctId":"NCT03231085","phase":"NA","title":"Comparison of the Rate of Preoperative Haemoglobin After Administration of Epoetin Alpha Associated With an Oral Medical Supplementation Versus Intravenous Before Surgery of Craniosynostosis at the Child","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2017-10-31","conditions":"Craniosynostosis","enrollment":100},{"nctId":"NCT02807558","phase":"PHASE2","title":"A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Syros Pharmaceuticals","startDate":"2016-09-20","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":155},{"nctId":"NCT03682536","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2019-01-02","conditions":"Myelodysplastic Syndromes","enrollment":363},{"nctId":"NCT05810311","phase":"PHASE2","title":"The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy","status":"NOT_YET_RECRUITING","sponsor":"Region Stockholm","startDate":"2025-06-01","conditions":"Diabetes Complications, Diabetes; Nephropathy (Manifestation)","enrollment":30},{"nctId":"NCT02251041","phase":"PHASE2","title":"Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2014-09","conditions":"Reperfusion Injury","enrollment":143},{"nctId":"NCT06466785","phase":"PHASE3","title":"A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis","status":"RECRUITING","sponsor":"Genexine, Inc.","startDate":"2024-01-25","conditions":"Anemia of Chronic Kidney Disease","enrollment":429},{"nctId":"NCT03446612","phase":"PHASE2","title":"Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-01-10","conditions":"Anaemia","enrollment":6},{"nctId":"NCT04432662","phase":"PHASE2","title":"Darbepoetin in Neonatal Encephalopathy Trial","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2021-05-28","conditions":"Neonatal Encephalopathy","enrollment":150},{"nctId":"NCT03071861","phase":"PHASE2","title":"Mild Encephalopathy in the Newborn Treated With Darbepoetin","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2017-12-01","conditions":"Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy Mild","enrollment":28},{"nctId":"NCT03339596","phase":"PHASE2","title":"Effects of Erythropoietin for Cognitive Side-effects of ECT","status":"COMPLETED","sponsor":"Martin Balslev Jørgensen","startDate":"2017-06-26","conditions":"ECT, Cognitive Impairment, Unipolar Depression","enrollment":60},{"nctId":"NCT03315897","phase":"PHASE2","title":"Effects of Erythropoietin on Cognition and Neural Activity in Mood Disorders","status":"COMPLETED","sponsor":"Lars Vedel Kessing","startDate":"2017-07-05","conditions":"Bipolar Disorder, Cognitive Impairment, Unipolar Depression","enrollment":103},{"nctId":"NCT05699109","phase":"","title":"Erythropoiesis Stimulating Agents for Anemia Management in Egyptian Hemodialysis Patients","status":"COMPLETED","sponsor":"Helwan University","startDate":"2021-01-01","conditions":"Anemia of Chronic Kidney Disease, Chronic Renal Failure, Chronic Renal Failure Anemia","enrollment":127},{"nctId":"NCT05585658","phase":"PHASE1, PHASE2","title":"A Randomized, Double-blinded, Active Controlled Crossover Clinical Trial to Investigate PK, PD and Safety of GBPD002","status":"COMPLETED","sponsor":"Globe Biotech Limited","startDate":"2021-10-16","conditions":"Natural Blood and Blood Product Toxicity","enrollment":42},{"nctId":"NCT05080049","phase":"PHASE3","title":"Erythropoietin to Improve Critical Care Patient Outcomes","status":"UNKNOWN","sponsor":"University Hospital, Angers","startDate":"2022-01-28","conditions":"Anemia, Intensive Care","enrollment":42},{"nctId":"NCT05422755","phase":"","title":"The Clinical Study to Evaluate Immunogenicity of Epodion® in Anemia Associated With CKD Patients","status":"COMPLETED","sponsor":"PT. Daewoong Infion","startDate":"2019-09-30","conditions":"Chronic Kidney Disease (CKD)","enrollment":200},{"nctId":"NCT05373303","phase":"NA","title":"The Clinical Study for Evaluating The Safety And Efficacy Of Epodion®","status":"COMPLETED","sponsor":"PT. Daewoong Infion","startDate":"2019-11-07","conditions":"Chronic Kidney Disease (CKD)","enrollment":82},{"nctId":"NCT04959578","phase":"PHASE4","title":"Comparison of Darbepoetin Alpha and Recombinant Human Erythropoietin for Treatment of Anemia in Children With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Rufaida Mazahir","startDate":"2018-02-01","conditions":"Anemia of Chronic Kidney Disease","enrollment":50},{"nctId":"NCT02075970","phase":"PHASE2","title":"Optimized Erythropoietin (EPO) Treatment","status":"COMPLETED","sponsor":"John A Widness","startDate":"2014-06","conditions":"Neonatal Anemia","enrollment":62},{"nctId":"NCT00687258","phase":"PHASE2","title":"Evaluation Of A New Vitamin E-Bonded Membrane On Anemia And Oxidative Stress In End-Stage Renal Disease Patients","status":"COMPLETED","sponsor":"A. Manzoni Hospital","startDate":"2006-07","conditions":"Anemia","enrollment":20},{"nctId":"NCT00513240","phase":"PHASE1, PHASE2","title":"Erythropoetin Neuroprotection for Neonatal Cardiac Surgery","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2006-09","conditions":"Congenital Heart Disease, Hypoplastic Left Heart Syndrome, Transposition of the Great Arteries","enrollment":62},{"nctId":"NCT03408639","phase":"PHASE3","title":"Comparing Efficacy and Safety of CinnaGen Beta Erythropoietin (CinnaPoietin®) Versus Eprex® on the Treatment of Anemia in ESRD Hemodialysis Patients","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2016-06-22","conditions":"Anemia in End-Stage Renal Disease","enrollment":156},{"nctId":"NCT00270478","phase":"PHASE1","title":"Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2005-12-21","conditions":"Sickle Cell Disease, Chronic Kidney Disease, Pulmonary Hypertension","enrollment":7},{"nctId":"NCT03521713","phase":"PHASE3","title":"To Evaluate the Efficacy, Safety, and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex)","status":"UNKNOWN","sponsor":"Dong-A ST Co., Ltd.","startDate":"2016-03-01","conditions":"Anemia of Chronic Kidney Disease","enrollment":214},{"nctId":"NCT02496377","phase":"NA","title":"Cross Iron (Comparative Randomized Oral Versus Systemic IRON)","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2014-08-29","conditions":"Allogenic Transfusion, Perioperative Anaemia, Knee Arthroplasty","enrollment":100},{"nctId":"NCT01868477","phase":"PHASE2","title":"Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-01-28","conditions":"Low and Int 1-risk Myelodysplastic Syndrome","enrollment":28},{"nctId":"NCT01695759","phase":"PHASE3","title":"Clinical Efficacy of Two Erythropoietin Drug in Participants With Secondary Anemia to Chronic Kidney Disease.","status":"TERMINATED","sponsor":"Azidus Brasil","startDate":"2013-12","conditions":"Chronic Kidney Disease, Anemia","enrollment":92},{"nctId":"NCT02439697","phase":"NA","title":"A Cohort Study of Conversion From Aranesp® to NESP® for the Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2015-11","conditions":"Anemia, End Stage Renal Failure on Dialysis","enrollment":50},{"nctId":"NCT02031289","phase":"PHASE4","title":"Impact of Preoperative Treatment of Anemia and Iron Deficiency in Cardiac Surgery on Outcome.","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2013-12","conditions":"Anemia, Iron Deficiency","enrollment":1003},{"nctId":"NCT00661505","phase":"PHASE3","title":"A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-05-14","conditions":"Anemia","enrollment":132},{"nctId":"NCT03286712","phase":"PHASE4","title":"The Effect on Vascular Reactivity Using the Erythropoeitin Alpha on Incident Peritoneal Dialysis Patients","status":"COMPLETED","sponsor":"National Kidney and Transplant Institute, Philippines","startDate":"2015-10","conditions":"Chronic Kidney Disease, Anemia, Complication of Peritoneal Dialysis","enrollment":30},{"nctId":"NCT02049346","phase":"PHASE4","title":"Comparison Among Erythropoietin Stimulating Agents","status":"COMPLETED","sponsor":"Hamad Medical Corporation","startDate":"2012-03","conditions":"Anemia of End Stage Renal Disease","enrollment":327},{"nctId":"NCT01417377","phase":"","title":"An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Anemic Patients With Chronic Kidney Disease (NORM)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-05-31","conditions":"Anemia","enrollment":22},{"nctId":"NCT00248339","phase":"PHASE3","title":"Trial of Peg-interferon Plus Epoetin-alfa for Treatment of Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2002-05","conditions":"Hepatitis C","enrollment":150},{"nctId":"NCT00286182","phase":"PHASE2","title":"Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)","status":"COMPLETED","sponsor":"Mathew S. Maurer","startDate":"2007-07","conditions":"Anemia","enrollment":56},{"nctId":"NCT01383460","phase":"PHASE3","title":"Efficacy of Granulocyte Colony-stimulating Factor and Erythropoetin for Patients With Acute-on-chronic Liver Failure","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2011-07","conditions":"Acute on Chronic Hepatic Failure","enrollment":55},{"nctId":"NCT00842621","phase":"","title":"Long Term Effects of Erythrocyte Lysis","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2009-03","conditions":"Sickle Cell Disease, Hemolytic Anemia","enrollment":390},{"nctId":"NCT00144755","phase":"PHASE3","title":"R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"Lymphoma Study Association","startDate":"2003-12","conditions":"Diffuse Large Cell Lymphoma","enrollment":600},{"nctId":"NCT01538771","phase":"PHASE2","title":"Intracoronary Darbepoetin-alpha to Reduce The Infarct Size and Post-Infarct Remodeling","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2009-11","conditions":"Myocardial Infarction","enrollment":80},{"nctId":"NCT02181348","phase":"PHASE1, PHASE2","title":"Effect of Vitamin E Supplementation on Hemoglobin Levels in Healthy Adults","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2008-11","conditions":"Anemia","enrollment":357},{"nctId":"NCT00267007","phase":"PHASE2","title":"A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy","status":"TERMINATED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-06","conditions":"Peripheral Neuropathy, Chemotherapy-induced","enrollment":32},{"nctId":"NCT00511901","phase":"PHASE4","title":"Prevalence and Treatment of Anemia in Rehabilitation Patients","status":"TERMINATED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2005-11","conditions":"Anemia","enrollment":22},{"nctId":"NCT01384565","phase":"PHASE3","title":"G-CSF and Erythropoetin in Survival of Patients With Decompensated Liver Disease","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2011-07","conditions":"Chronic Liver Disease","enrollment":55},{"nctId":"NCT00526747","phase":"","title":"Erythropoietin Resistance in Anemia of Chronic Kidney Disease","status":"COMPLETED","sponsor":"Duke University","startDate":"2007-08","conditions":"Anemia, Kidney Failure, Erythropoietin","enrollment":32},{"nctId":"NCT00524901","phase":"PHASE2","title":"Study of the Use of a Single Dose of Erythropoietin to Treat Acute Myocardial Ischemia","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2007-09","conditions":"CABG, Coronary Artery Disease","enrollment":10},{"nctId":"NCT01758861","phase":"PHASE2","title":"Effect of Erythropoietin on the Incidence of Acute Kidney Injury Following Complex Valvular Heart Surgery","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2011-07","conditions":"Acute Kidney Injury","enrollment":98},{"nctId":"NCT00944684","phase":"PHASE2","title":"High Dose Ribavirin in the Treatment of Chronic Hepatitis C","status":"COMPLETED","sponsor":"University of Bern","startDate":"2007-11","conditions":"Chronic Hepatitis C","enrollment":32},{"nctId":"NCT01392612","phase":"PHASE4","title":"Erythropoietin and Platelet Activation Markers","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2006-11","conditions":"Thrombosis, Hypertension","enrollment":12},{"nctId":"NCT00719498","phase":"PHASE3","title":"Effect of Early High-dose Epoetin Alfa During Cardiac Arrest (Pilot Study)","status":"COMPLETED","sponsor":"Janssen Cilag S.A.S.","startDate":"2003-11","conditions":"Resuscitation, Cardiopulmonary, Cardiac Arrest","enrollment":20},{"nctId":"NCT00446576","phase":"PHASE3","title":"The Effect of Epoetin Alfa on Cardiac Function and Quality of Life in Patients With Early Renal ((Kidney) Disease","status":"COMPLETED","sponsor":"Janssen-Cilag B.V.","startDate":"1999-11","conditions":"Anemia","enrollment":176},{"nctId":"NCT00425698","phase":"PHASE2, PHASE3","title":"Erythropoietin (EPO) and Ischemia-reperfusion After Kidney Transplantation","status":"COMPLETED","sponsor":"Hannover Medical School","startDate":"2007-02","conditions":"Kidney Transplantation","enrollment":88},{"nctId":"NCT00691613","phase":"NA","title":"Infusion of a Single Dose of Erythropoietin to Prevent Injury in an Ischemia Reperfusion Forearm Model","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2010-07","conditions":"Ischemia-Reperfusion Injury, Myocardial Infarction","enrollment":12},{"nctId":"NCT00557817","phase":"PHASE2, PHASE3","title":"Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT)","status":"COMPLETED","sponsor":"University of Liege","startDate":"2004-03","conditions":"Hematological Malignancies","enrollment":125},{"nctId":"NCT00399269","phase":"PHASE3","title":"Efficacy & Safety Study of Recombinant Human Erythropoietin -Alpha, in Patients With Anemia of Chronic Renal Failure","status":"COMPLETED","sponsor":"Cadila Pharnmaceuticals","startDate":"2006-12","conditions":"Anemia","enrollment":100},{"nctId":"NCT00234143","phase":"PHASE2, PHASE3","title":"Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)","status":"UNKNOWN","sponsor":"St. Bartholomew's Hospital","startDate":"2004-10","conditions":"Myelodysplastic Syndromes","enrollment":360},{"nctId":"NCT00443339","phase":"PHASE2","title":"Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)","status":"UNKNOWN","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2006-12","conditions":"Myelodysplastic Syndromes","enrollment":99},{"nctId":"NCT00189371","phase":"PHASE3","title":"Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum","status":"TERMINATED","sponsor":"AGO Study Group","startDate":"2004-02","conditions":"Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum, Platinum Sensitve Relapse, Anemia","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":85,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Erythropoietin alpha (Epogen)"],"phase":"phase_2","status":"active","brandName":"Erythropoietin alpha","genericName":"Erythropoietin alpha","companyName":"Mathew S. Maurer","companyId":"mathew-s-maurer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Erythropoietin alpha stimulates erythropoiesis by binding to the erythropoietin receptor. Used for Anemia associated with chronic kidney disease, Anemia associated with chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}